Last-Resort radiation therapy shows promise for rare childhood and adult cancers
NCT ID NCT01850888
First seen Nov 10, 2025 · Last updated May 12, 2026 · Updated 24 times
Summary
This study gave a special radioactive drug (131I-MIBG) to 15 patients with advanced neuroblastoma or pheochromocytoma who had run out of standard treatments. The goal was to see if it could shrink tumors and ease symptoms, while tracking side effects. Patients received different doses based on their health and stem cell availability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.